AVACTA GROUP PLC - Investor Presentation

In this episode, we explore Avacta Group PLC's innovative FAP Activated Precision dual Payload Platform, a significant advancement in cancer treatment. This platform uses a peptide drug conjugate that selectively releases a potent cancer drug in tumor environments rich in fibroblast activation protein (FAP), ensuring high localized drug concentrations and potentially reducing side effects. We discuss how the dual payload mechanism effectively targets cancer resistance by delivering two drugs simultaneously to enhance treatment efficacy. The platform demonstrates a strong safety profile, with early trial data suggesting no serious side effects. As development progresses, there is potential for broader applicability across various solid tumors, with clinical trials for the single and dual payload drugs anticipated to begin in 2026.